BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2017 earnings on Tuesday, August 8 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 8, 2017. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.Jul 31, 2017
The Research Division of BioTelemetry
BioTelemetry Research is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 600,000 patients and subjects a year. In addition to industry-leading global cardiovascular monitoring, we provide advanced imaging services for oncology, cardiovascular, metabolic diseases, neurologic, musculoskeletal imaging.
San Diego, CA - Booth #41
Join BioTelemetry Research experts, for two days of constructive networking and in-depth presentations on the latest challenges and developments facing the clinical operations and outsourcing community in Southern California.Sep 27-28, 2017
Publications / White Papers
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries…
Join Polina Voloshko, MD, Chief Medical Officer and Daniel Goodman, MD, Vice President and Medical Director, to learn about specific cardiovascular issues in oncology drug development that conveys current thinking from regulatory, academic and industry perspectives, with a focus on practical solutions that can be readily implemented in the clinical development arena.
More Register Register